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Abstract: Zinc, the essential trace element, is known to play multiple biological functions in hum an organism.
This m etal is a component of m any structural as well as regulatory and catalytic proteins. The precise regula­
tion of zinc homeostasis is essential for central nervous system and for the whole organism. Zinc plays a sig­
nificant role in the brain development and in the proper brain function at every stage of life. This article is a 
review  of knowledge about the role o f zinc in central nervous system (CNS) function. The influence o f this bio­
m etal on etiopathogenesis, prevention and treatment of selected brain diseases and disorders was discussed.
Zinc imbalance can result not only from insufficient dietary intake, but also from impaired activity o f zinc trans­
port proteins and zinc dependent regulation o f m etabolic pathways. It is know n that some neurodegenerative 
processes are connected with zinc dyshomeostasis and it m ay influence the state o f A lzheim er’s disease, depres­
sion and ageing-connected loss of cognitive function. The exact role of zinc and zinc-binding proteins in CNS 
pathogenesis processes is being under intensive investigation. The appropriate zinc supplementation in brain 
diseases may help in the prevention as well as in the proper treatm ent o f several brain dysfunctions.
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Zinc plays an essential role in the number of 
biochemical processes crucial for cell survival (Fig. 
1). Evidently, unbalanced homeostasis of this bio­
metal affects cell function. This bivalent metal con­
stitutes a prostetic group of a number of enzymes 
like carbonic anhydrase, alcohol dehydrogenase, 
alkaline phosphatase, phospholipase C, carboxypep- 
tidase, Zn-Cu superoxide dismutase (SOD) and oth­
ers regulatory proteins (1, 2). It is also a critical 
component of DNA and RNA polymerases and has
a fundamental role for nucleic acid metabolism and 
gene activation and repression. At the transcription­
al level of protein expression, zinc fingers structure 
enables transcription factors to anchor to DNA helix 
(3). This biometal regulates cell cycle by the influ­
ence on cyclines and cyclin-dependent kinases (4). 
The activities of many growth factors are zinc 
dependent, hence cell proliferation is regulated by 
the concentration of zinc ions (5). Zinc regulates 
microtubule polymerization process in the division
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of cells, providing the correct cell cytoskeletal for­
mation and cell mitosis (4).
One of the most important functions of zinc in 
organism is an antioxidative protection (6, 7). Zinc 
decreases ROS generation by several mechanisms. 
Firstly, the zinc antioxidative effect occurs through 
activity of zinc dependent enzyme, superoxide dis- 
mutase (1). Secondly, zinc metallothioneins (MT) 
can bind and neutralize ROS due to their sulfhydryl 
groups (7). Additionally, zinc ions have influence on 
signal transduction pathway via inhibition of NF- 
k B, TGFB1 and MAPK (8, 9).
Zinc activity occurs through inhibition of cas- 
pases and protection from ROS-related release of 
cytochrome C from mitochondria and this way sup­
presses apoptosis induction process (9). It was 
established that zinc in hippocampus could inhibit 
cell apoptosis and prevent mitochondrial dysfunc­
tion through the activation of BDNF and the regula­
tion of TrkB pathway (9). The proper zinc balance 
and the expression of zinc transporters in organism 
is crucial for anticancerogenic protection (7, 10), 
because optimal zinc levels have an impact on 
growth factors and cytokines, which enables to 
remove malicious cells in apoptosis process. Other 
mechanism of cell protection by zinc ions is accord­
ing to expression and folding regulation of tumor 
suppressor genes products. Notably, this metal ion is 
crucial for immunoregulation due to decreasing the 
synthesis of TNF-a, and other interleukin proin- 
flammatory cytokines (7). Zinc is also indispensable 
for proliferation and proper function of T lympho­
cyte subpopulations (11). Additionally, zinc ions are 
necessary for proper hormonal balance and in this 
way exert the effect on the whole organism (5, 12). 
Zinc ions are components of hormones (i.e., thymus 
hormones) or regulate hormones synthesis and 
ensure the appropriate hormone trails (i.e., insulin). 
The disturbances in zinc homeostasis are important 
causative factors of unbalanced organism function­
ing, which may lead to inflammation process and 
the development of diseases like arthritis, ulcers, 
cancer, and brain disorders (10).
Zinc absorption and transport
The total content of zinc in the adult human 
body is approximately 2 grams (10, 13). The 
requirement for this element for adult women is 
about 8 mg and for adult men about 11 mg per day 
and the similar amount is excreted daily (14). There 
is no mechanism enabling to store zinc in the body 
so it should be ingested regularly. In physiological 
conditions, zinc homeostasis strictly depends on 
maintaining its amounts on stable level in the organ­
ism. The importance of keeping zinc homeostasis is 
reflected by the complexity of zinc transport into 
and inside the cells (15, 16). There are two families 
of mammalian specific zinc transporters identified: 
ZIP/SLC39 family transporter, which transports 
zinc into the cytoplasm and ZnT/CDF/SLC30 fami­
ly transporter, which acts in efflux zinc ions from 
the cell. Zinc transporters expression is regulated by 
zinc level in cytoplasm and outside the cells, accord­
ing to the cell type and function, by zinc dependent 
transcription factors, especially metal regulatory 
transcription factor 1 (MTF1) (1, 16).
In human, the dietary zinc is mostly absorbed 
in duodenum, ileum and jejunum by active transport 
trough ZIP4/SLC39A4 zinc transporter, localized on 
the apical surfaces of the enterocytes (16). However, 
there are other zinc uptake possibilities in the intes­
tinal tract i.e., ZIP1/SLC39A1 transporter expressed 
in small intestine, divalent metal-ion transporter 1 
(DMT1/DCT1/SLC11A2) as well as copper trans­
porter 1 (CTR1/SLC31A1) (16, 17). Zinc absorption 
can be affected by cations like copper, chromium, 
calcium, manganese and cadmium ions that can 
compete for zinc transporters (15, 17). The process 
of absorbance, transport and bioavailability may be 
affected by diet composition. The influence of diet 
components on zinc absorption and reabsorption 
was a subject of interest (18).
It is known that zinc ions in cell cytoplasm are 
accumulated bound to metallothionein proteins (1, 
15). Further zinc transport from enterocytes into the 
bloodstream occurs through the ZnT1 transporter. 
Zinc ions in the blood are transported as complexes 
with albumins (52%), macroglobulins (40%), and 
amino acids (8%). In human serum there is about 15 
pM/L of zinc and this concentration is similar to that 
in other mammals (10, 16). Zinc is absorbed to tis­
sues and cells from blood mostly by ZIP1 and ZIP4 
zinc transporters, and then, inside the cells, with 
both, ZIP and ZnT family (ZnT2/SLC30A2, 
ZnT4/SLC30A4, ZnT5/SLC30A5, ZnT6/SLC30A6, 
ZnT7/SLC30A7, ZIP7/SLC39A7, ZIP8/SLC39A8) 
to nucleus or other cell compartments, where it plays 
catalytic roles or is stored in Golgi apparatus vesi­
cles (15-17). Zinc is excreted from cells by the zinc 
efflux transporter ZnT1/SLC30A1 and is eliminated 
from the organism with feces (over 10 mg/day) and 
urine (0.4 mg/day) (10).
The role of zinc in brain function
Zinc is transported from blood trough blood 
brain barrier system, mostly in the form of com­
plexes with amino acids, especially L-histidine and 
cysteine (15, 19). Zinc transport in nervous cells is
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shown in Figure 1. The average zinc concentration 
in brain is between 10 and 15 pg/g wet tissue (13), 
however, it may vary in different brain parts. The 
highest zinc level in the brain was found in hip­
pocampus, amygdala and cerebellum (13, 19). There 
are three pools of zinc considered in the brain (15, 
21). First, about 90% of total zinc, is the metal tight­
ly bound to proteins. Second pool includes about 
10% of brain zinc, which is present in a form of 
ions; this pool is stored in presynaptic vesicles of 
glutamatergic neurons where it is transported by 
specific transporter ZnT3/SLC30A3. Third pool, 
free zinc ions in non-precised compartments, is less 
than 1%. The measured zinc contents, especially in 
last two (labile, chelatable) pools vary depending on 
sample preparation method and measurement tech­
niques (13, 19).
This element is reported to have a second mes­
senger activity in the brain (22). Accordingly, in 
mammals zinc containing vesicles were found most­
ly in the glutamatergic neurons in brain cortex, hip­
pocampus and amygdala, brain compartments 
responsible for learning, memory, cognition and 
mood regulation (10, 23, 24). During the neuronal 
activity, when zinc with glutamate is released from 
synaptic vesicles into synaptic cleft, zinc interac-
Figure 1. The mechanisms of zinc action in the organism. The 
scheme presents zinc action including the level o f the particular 
cells and the whole organism as an integral system (1, 2)
tions with postsynaptic receptors may occur. The 
well known process of zinc inhibition of NMDA 
receptors in synapses occurs through two mecha­
nisms, voltage independent allosteric inhibition, 
which reduce ion cannel opening frequency, and 
voltage dependent inhibition by blocking open chan­
nels (21, 25). Another interaction mechanism con­
sists of inhibition of GABA receptor-mediated 
response, which leads to reduction of neuronal 
excitability. Furthermore, zinc can enhance AMPA 
receptors in postsynaptic cells and in that way zinc 
may regulate cell excitation (22, 25). Extracellular 
zinc in synaptic cleft may be reuptaken by both pre- 
and postsynaptic neurons and also glial cells (22).
The adequate zinc level is critical for CNS 
development and the differentiation of nervous stem 
cells in mammals (9, 26). The sustainable zinc 
homeostasis is necessary for the proper development 
of brain, especially for cerebellum, stellate, basket 
and also for Purkinje and granule cells. It was 
observed, that in the developing rat brain zinc accu­
mulates in those cells, which should be eliminated 
for proper development (26). On the other hand, 
inadequate zinc status affects growth and maturation 
of neurons by disturbing zinc-dependent receptor 
functions. The rat model experiments showed 
decreased proliferation of neural precursor cells in 
adults as a result of the postnatal zinc deficiency (9). 
Studies with primary cultures of rat cortical neurons 
and human neuroblastoma IMR-32 cells proved that 
low zinc level reduced cell viability, decreased cell 
proliferation and increased neuronal apoptotic cell 
death (8). Zinc regulative role in the cortical plastic­
ity is important for brain development and function­
ing of processes like learning and memory (25, 26). 
The experiments with cultured rat cortical neurons 
and hippocampal slices showed that zinc ions can 
transactivate TrkB through pathway independent on 
neurotrophins. Zinc can modulate long-term poten­
tiation (LTP), long term depression (LTD) and 
synaptic plasticity in this process (25). Additionally, 
zinc may increase postsynaptic density of excitatory 
synapses in BDNF activation pathway (9).
The elevated zinc level, about 300 pM extra­
cellular and over 400 nM intracellular (10, 27), is 
toxic to neurons. The experiments with cultured cor­
tical neurons demonstrated that elevated zinc con­
centrations result in lower ATP synthesis caused by 
inhibition of glycolytic pathway enzymes such as 
glyceric aldehyde 3-phosphate dehydrogenase and 
phosphofructokinase and that way affects cells sur­
vival (27). The synaptically released extracellular 
zinc can reach the toxic amounts during pathologi­
cal states like seizure, cerebral ischemia and trau­
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matic brain injury (21, 27). Moreover, other obser­
vations indicate that glucose starvation may increase 
zinc ions toxicity for rat cerebellar granule neurons 
(29). In proposed mechanism, a lack of glucose 
induces activation of NMDA-channels and growing 
accumulation of calcium and zinc ions in mitochon­
dria, which lead to severe neuronal damage. 
However, in neuroblastoma IMR-32 cell in vitro 
model, it was shown that high concentrations of zinc 
ions may reduce toxic effect of other toxic metals (8, 
17).
Disturbances of zinc homeostasis are consid­
ered as important factors in neurodegenerative brain 
disorders. Adequate zinc intake is crucial for proper 
cognitive functions, especially in children and elder­
ly human (19, 23, 24, 26, 30, 31). The alterations in 
zinc level have been reported in such diseases as 
depression and ADHD, Alzheimer’s disease (AD), 
Parkinson’s disease (PD) as well as in brain 
ischemia and traumatic brain injury.
The role of zinc in ischemic brain injury
In the conditions of brain ischemia, which can 
be caused by stroke and traumatic brain injury, zinc 
ions seem to play an important role in the neuronal 
damage process (27, 28). The synaptically released 
zinc ions are proposed as a critical component of the 
excitotoxicity cascade occurring in the course of
ischemia (27). During ischemia, oxygen deficit 
results in increasing acidosis (21). In turn, acidosis 
can trigger more zinc release from MT proteins, 
which was demonstrated in vitro in rat-cultured neu­
rons (21, 27, 28). Therefore in the conditions of 
growing oxidative stress typical for ischemia, addi­
tional MTs release of zinc ions can finally lead to 
apoptosis of neurons and glial cells (27). In addition, 
in vitro studies demonstrated that zinc insults affect 
cellular respiration and ATP depletion (27). 
Moreover, when ATP deficits cause progressive 
depolarization and affect ionic homeostasis of the 
cells, the repetitive waves of zinc release from 
synaptic vesicles into extracellular space were 
observed (27). The spreading depolarization and 
intensive zinc efflux can increase intracellular calci­
um flow (21) and that way calcium and zinc ions 
may work synergistically causing neurotoxicity 
(21). This results in alterations of plasma mem­
branes permeability, mitochondrial damage and 
release of glutamate from neuronal vesicles (27, 28). 
In ischemic conditions large amounts of zinc may 
enter postsynaptic neurons through routes that are 
normally used by calcium. The studies with rat cor­
tical neurons primary cultures showed, that zinc ions 
were influxed to postsynaptic neurons and glial cells 
after depolarization through voltage dependent cal­
cium channels (21, 25). Additionally, this process
Figure 2. The mechanisms o f zinc transport in nervous system. The direction o f zinc ions flux presented with arrows; black circles -  ZnT 
family o f zinc transporters, black triangles -  ZIP family of zinc transporters , black square -  DMT1 transporter, MT3 -  metallothionein 3 
(neuron specific protein) (10, 15, 16, 24, 32)
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may be enhanced by activity of glutamate, which, as 
mentioned, is released altogether with zinc (32). The 
rising glutamate amounts in extracellular space may 
cause additional opening of calcium channels lead­
ing to increased excitotoxicity (21). The studies on 
animal ischemic models confirmed extracellular 
accumulation of high zinc amounts in neurons and 
in extracellular space (27, 32).
On the other hand, it was demonstrated in 
ischemic state models that zinc chelation can 
decrease zinc accumulation and therefore degrada­
tion of nervous cells (27). However, there is also 
evidence that in ischemic conditions high zinc ions 
level may exert a neuroprotective effect (19). It is 
presumed that zinc downregulates the NMDA 
receptors and in that way may decrease toxicity of 
calcium ions (21, 25). Also the effectiveness of zinc 
bondage to metallothioneins may play a protective 
role in the brain injury (32). Zinc-dependent antiox­
idative enzymes may also have beneficial effect in 
conditions of ion dyshomeostasis caused by 
ischemia. In vitro studies with hippocampal rat neu­
rons confirmed important role of proper zinc trans­
port during ischemia (27, 28), because very high 
zinc concentrations (150 mM/L) were shown to 
increase (transiently) ZnT1 mRNA level in cells. 
These findings suggest that increased ZnT1 expres­
sion could be a defense mechanism from delayed, 
zinc-related neuronal damage caused by elevated 
zinc efflux (27, 32).
In reperfusion process, which follows 
ischemia, changes of zinc concentration in particular 
compartments can be continuously injuring for neu­
rons (27, 28) but exact mechanism of action is under 
investigation. However, the effect of regulation is 
not clear, because inflammation process occurs in 
parallel, where zinc is ascribed to play beneficial 
role.
All presented findings and mixed data indicate 
that proper zinc level in specific neuronal compart­
ments is essential for brain function and need to be 
precisely controlled in narrow concentration range, 
since even slightly disturbance may lead to neuronal 
damage during pathological ischemic conditions.
The role of zinc in depression
Despite of intensive clinical studies on depres­
sive disorders, it is difficult to elucidate its patho­
physiology. The most probable causes are connect­
ed with the loss of homeostasis of the stress hor­
mones, neurotransmitters, neurotrophic factors, and 
additionally, disturbed trace elements levels (33, 
34). Moreover, all those factors apply to only some 
types of depressed patients but not for others.
Regardless of exact cause of this disease, the 
increased neuronal death by ROS formation and 
inflammation was postulated in most cases (35). The 
excessive inflammation process in depressed 
patients is manifested by elevated levels of pro 
inflammatory mediators (IL-1, IL-2, IL-6, TNF-a, 
IFN-y) (35). As it was mentioned before, disregula­
tion of inflammatory pathways may be correlated 
with decreased zinc level. In zinc deficiency condi­
tions the proper function of immune system, differ­
entiation of the immune cells and response of T 
helper lymphocytes is usually inappropriate. 
Schmidt considered that early life stress is a major 
risk factor for development of later depression due 
to affected neurogenesis in brain, especially in hip­
pocampus (33, 34). On the molecular level, these 
processes may be zinc-dependent via antioxidative 
activity changes and its influence on proper course 
of brain development process. Additionally, Takeda 
hypothesized that corticosterone-mediated increase 
in postsynaptic zinc signal may decrease synaptic 
plasticity LPT and in that way affects hippocampal 
functions and in consequence induces depression in 
chronic stress conditions (36). Animal models of 
depression are commonly based on measuring acute 
or chronic stress, i.e., in FST and TST or chronic 
mild stress (CMS). It was observed that administra­
tion of zinc as well as antidepressants could reduce 
the durance of depressed behavior of animals in 
these models (33, 37). The other rodent models of 
depression are based on diet zinc-deprived, which 
can also generate depression-like behavior. These 
findings were consistent with clinical evidences, 
especially obtained in the treatment resistant cases 
when patients with depression had significantly 
lower serum zinc level compared to non-depressed. 
On the other hand, it has been reported that success­
ful depression therapy can lead to zinc level normal­
ization (33).
The important zinc dependent mechanism, 
which disturbances may exert influence on depres­
sion in patients is neuromodulation of NMDA 
receptors (25). The altered regulation of these recep­
tors may lead to the development of depression 
symptoms. As previously mentioned, zinc ions 
released in synaptic cleft causes effective inhibition 
of NMDA receptors. The antidepressant mecha­
nism, proposed by Duman and Violets, is based on 
rapid induction of synaptogenesis by NMDA recep­
tor inhibition agents (34). Additionally, important 
role in the synaptogenesis is also played by NGF, 
BDNF and neurotrophins, which concentrations can 
be reduced by stress in rodents and in depressed 
human patients (37, 38). Moreover, it was demon­
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strated that zinc supplementation could increase 
BDNF protein level in rodents (38).
In a view of these findings, it seems obvious 
that there is a relationship between zinc homeostasis 
and depression progress in humans. Unfortunately, 
there is no exact in vitro cell culture model of 
depression, which could help study the exact mech­
anisms in physiologically active nervous cells.
The role of zinc in Alzheimer’s disease
Alzheimer’s disease is an age-related neurode- 
generative disorder manifested by the progressive 
dementia. It is well documented that brains of AD 
patients typically exhibit intracellular neurofibril­
lary tangles deposits of т protein and extracellular 
ß-amyloid plaques (39). However, the exact mech­
anism of neurodegeneration in AD is unclear and 
still there is no effective therapy of this disease. 
Clinical examinations data revealed the noticeable 
disturbances in zinc concentration in serum, brain 
cells and compartments and in synaptic vesicles of 
AD patients compared with control subjects (19, 
23). It was considered that etiology of AD might 
involve abnormal concentration and disturbed com- 
partmentalization of zinc ions. Indeed, increased 
concentration of extracellular zinc ions in the brain 
can be of importance in AD pathogenesis (40, 41). 
It has been demonstrated that ß-amyloid plaques 
contain high concentrations of metal ions, especial­
ly iron, copper and zinc. In addition, results of in 
vitro studies demonstrated that zinc binding could 
accelerate the ß-amyloid peptide formation (42). In 
consistence with these findings, it was observed 
that the formation of amyloid plaques in APP trans­
genic mice (AD model with mutations of amyloid 
precursor protein) was effectively inhibited due to 
the application of metal chelating agents. The main­
tenance of proper zinc concentration is crucial, 
because the enzymes, which restrain abnormal fold­
ing and aggregation of the ß-amyloid such as 
neprilysin and insulysin, are zinc dependent pro­
teins (39).
The changes in zinc levels can be caused by the 
altered expression of zinc transporters, especially 
ZnT1, ZnT3, ZnT4, ZnT6 and MT proteins (24, 
40-42, 44). The extracellular concentration of zinc 
in hippocampus and cerebral cortex depends on the 
activity of zinc transporter ZnT3. The abnormally 
increased activity of ZnT3 may additionally elevate 
the extracellular zinc and in that way it induces the 
formation of ß-amyloid plaques. This process is 
thought to be the first step in zinc homeostasis dis­
ruption in course of that pathological state. The inhi­
bition of ß-amyloid concentration was observed in
brains of ZnT3 gene knock-out animals (Tg2576 
mice) (44). However, excessively reduced activity 
of ZnT3 transporter may affect signal transduction 
in neurons, which can result in memory difficulties. 
Beyer et al. (42) demonstrated that the AD severity 
is connected with the significant loss of ZnT3 
expression in the cortical regions of human brain. It 
was concluded that ZnT3-derived extracellular zinc 
pool is important for the proper regulation of normal 
cognitive function by modulation of the synaptic 
neurotransmission. The observations of ZnT3 gene 
knock-out mice behavior confirmed that animals 
exhibit deficits in learning and memory. W hat is 
more, the loss of memory functions were age- 
dependent and it is presumed that the adverse effects 
could be similar to those observed in AD patients, 
which underline the importance of proper expres­
sion of ZnT3 protein in specific regions for main­
taining the brain function (41, 45).
Thus, once disturbed zinc concentration and 
distribution can influence zinc transporters expres­
sion. The altered zinc homeostasis manifested in the 
elevated extracellular zinc state may in consequence 
lead to up-regulation of expression of ZnT1 protein, 
which in turn exports zinc ions outside cells (24, 
44). The raised concentration of extracellular zinc 
can be interpreted as a signal for the enhanced syn­
thesis of this zinc exporter. Finally, it results in the 
enormous zinc export outside cells and the aug­
mented zinc imbalance. The recent results demon­
strated the increased expression patterns of zinc 
transporting proteins ZnT1, ZnT3, ZnT4, ZnT6, 
and ZnT7 in brain vessels of mice model 
APPswe/PS1dE9 (44).
The additional zinc activity connected with AD 
development is revealed in the hyperphosphoryla­
tion of т protein. This phenomenon promotes poly­
merization of this protein and generation of neu­
rofibrillary tangles in AD neurons (46). Kim et al. 
(46) showed that zinc regulates phosphorylation of т 
protein through extracellular signal-regulated kinase 
pathway (MAPK/ERK); т protein deposits affect 
microtubule function in neurons and probably may 
be the important cause of neuronal death in AD.
The regulation tissue-distant metabolic transi­
tions by zinc, such as insulin synthesis and secretion 
pathways, may influence AD development. The 
recent experimental reports suggest the dependence 
between regulation of cells insulin sensitivity and 
AD pathogenesis, which ultimately qualify to name 
this disease as “diabetes type 3” (47).
The progressive loss of synaptic connections 
and the neuronal degeneration lead to the advance­
ment of dementia in AD pathogenesis (21). The
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influence of elevated ROS activity on the disease 
development is consistent with the frequently 
reported increased ROS formation observed in AD 
patient neurons. The explanation may be the failure 
in mitochondria functioning, which lead to the depo­
larization of mitochondrial membranes and in con­
sequence to the increased ROS activity (48, 49). It is 
obvious that ROS are especially harmful in CNS 
because of pro-oxidation of lipids, which are essen­
tial for proper nerve membranes function and also 
for the conductivity and signal transduction path­
ways. Summarizing, the role of zinc in the patho­
genesis of AD may be miscellaneous. Further stud­
ies are necessary to understand the complex role of 
zinc in the AD severity and treatment.
Other CNS disorders connected with zinc 
imbalance
There are recent clinical evidences that other 
CNS diseases may be correlated with zinc dyshomeo- 
stasis. The main symptoms of Parkinson’s disease in 
human are motoric dysfunctions and a decrease in 
kinetic abilities. This neurodegenerative disorder is 
the consequence of dopaminergic neurons damage 
resulted from the progressive deficiency of neuro­
transmitter dopamine (23, 47). The biochemical 
processes affected in PD may be correlated with dis­
ruptions of zinc homeostasis. Clinical studies with 
PD patients suggested significantly decreased zinc 
status in patient blood serum compared with healthy 
elders control group. Another meaningful observa­
tion concerned protein deposits connected with 
metal ions disturbances in patient brain compart­
ments, which showed some similarities to those 
observed in Alzheimer’s disease (23). Experiments 
in vitro on clonal CHO cell line with overexpressed 
D2 receptors showed that zinc ions may have influ­
ence on dopamine receptors modulation and in that 
way low zinc status could be another factor reducing 
dopamine activity (50). Additionally, lowered zinc 
concentration may have influence on pathophysiol­
ogy of PD by increased inflammation processes, 
generation of ROS and affected neurotropic factors 
levels, resulted in the proceeding neuronal degener­
ation.
As it was mentioned before, in the developing 
human brain, disrupted trace metal homeostasis may 
disturb the proper conduct of the process and in con­
sequence affect hippocampus functioning. This, in 
turn, may lead to the following: affected attention, 
memory and activity levels in human but especially 
can correlate with children affected behavior. The 
epidemiological and clinical studies showed that 
children with ADHD disorder had decreased level of
zinc in blood, hair and urine compared with control 
groups of children without attention problems (30). 
Additionally, the relation between effectiveness of 
methylphenidate and amphetamine derivatives used 
in ADHD treatment altogether with zinc supplemen­
tation was observed (51). Zinc role in ADHD disor­
der may be correlated with the activity of this bio­
metal as a second messenger in brain cells. In turn, 
positive zinc action on attention processes may be 
connected with zinc regulation of dopamine metab­
olism and transport (47, 51). However, double blind 
placebo controlled study by Bilici et al. (53) showed 
that beneficial effects of 150 mg/day zinc sulfate 
supplementation for 12 weeks on ADHD symptoms 
were limited and rather comparable with placebo. 
All these findings indicate necessity of further stud­
ies on zinc role in ADHD disorder.
In autism spectrum disorder (ASD) the progress 
of disease may interfere with adequate supply of trace 
elements. ASD is a neural development disorder char­
acterized by occurrence of repetitive behaviors and 
affected social interaction (31). Pathogenesis of this 
disorder is unknown but genetic, life-style and envi­
ronmental factors are being under consideration now. 
It was hypothesized that one of important factors may 
be early zinc deficiency combined with accumulation 
of other toxic metals. Preliminary studies showed that 
most of children exhibiting ASD symptoms had sig­
nificantly lowered zinc levels in hair (31). Also Faber 
et. al. suggested the importance of zinc deficiency and 
the probability of metallothionein detoxification sys­
tem disturbances in ASD pathogenesis (54). They 
hypothesized that plasma zinc/copper ratio may be 
considered as a one of biomarkers of autism suscepti­
bility in children. It was also reported that supple­
mentation of nutrients, including zinc, during infancy 
development, can reduce severity of ASD symptoms 
(31). However, the exact mechanisms of beneficial 
effects of Zn in etiology of this disorder are not 
proved enough.
On the basis of presented studies, disturbances 
of zinc balance during human life span seem to be 
an important factor correlated with development of 
CNS diseases.
CONCLUSIONS
Zinc plays an essential role in the number of 
processes crucial for proper cells and organism 
function. The most important, regulated by this bio­
metal, are gene expression, antioxidation defense 
and apoptosis. During human growth zinc can influ­
ence development and proper function of nervous 
system and neuronal plasticity. Specific zinc trans­
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porters strictly regulate the uptake of this ion into 
the organism. However, zinc concentration in the 
diet is important, due to the lack of mechanisms 
which allow to store this biometal for a long time. 
The zinc imbalance can result not only from insuffi­
cient dietary intake, but also from impaired activity 
of zinc transport proteins and zinc dependent regu­
lation of metabolic pathways. The crucial role of 
zinc homeostasis in CNS exhibits influence on prop­
er function of learning, cognition and mood regula­
tion. The adequate zinc levels in specific brain com­
partments seem to be critical for the proper brain 
functioning because even slight disturbances in zinc 
homeostasis may lead to or participate in the devel­
opment of several disorders.
The exact role of zinc and zinc-binding proteins 
in CNS pathogenesis processes is being under inten­
sive investigation. Therefore, the pressing issue is to 
dispel the doubts on the adequate zinc level in spe­
cific pools and find out how the concentration 
changes may be involved in the pathogenesis of dis­
eases and brain dysfunctions. Notably, there is a need 
to develop reliable methods of determination zinc 
disturbances in the brain with the potential to use 
them in diagnosis of neurodegenerative diseases. The 
crucial issue is also to determinate appropriate zinc 
supplementation in brain diseases prevention as well 
as in proper treatment. Many detailed mechanisms of 
zinc activity in living cells are known to date but fur­
ther research warrants understanding of complex 
influence of zinc on human organism.
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